Avacta Group (AVCT) Competitors GBX 47.70 +0.30 (+0.63%) As of 11:39 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesBuy This Stock AVCT vs. SLN, PRTC, OXB, HZD, FARN, VRP, ARIX, BVXP, CIR, and 4BBShould you be buying Avacta Group stock or one of its competitors? The main competitors of Avacta Group include Silence Therapeutics (SLN), PureTech Health (PRTC), Oxford Biomedica (OXB), Horizon Discovery Group plc (HZD.L) (HZD), Faron Pharmaceuticals Oy (FARN), Verona Pharma plc (VRP.L) (VRP), Arix Bioscience (ARIX), Bioventix (BVXP), Circassia Group (CIR), and 4basebio (4BB). These companies are all part of the "biotechnology" industry. Avacta Group vs. Its Competitors Silence Therapeutics PureTech Health Oxford Biomedica Horizon Discovery Group plc (HZD.L) Faron Pharmaceuticals Oy Verona Pharma plc (VRP.L) Arix Bioscience Bioventix Circassia Group 4basebio Silence Therapeutics (LON:SLN) and Avacta Group (LON:AVCT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, media sentiment, institutional ownership and valuation. Do insiders and institutionals hold more shares of SLN or AVCT? 10.2% of Avacta Group shares are owned by institutional investors. 32.9% of Avacta Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has preferable earnings and valuation, SLN or AVCT? Silence Therapeutics has higher earnings, but lower revenue than Avacta Group. Avacta Group is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSilence Therapeutics£11.35M0.00N/A-£48.60N/AAvacta Group£26.29M6.89-£30.08M-£7.77-6.14 Does the media refer more to SLN or AVCT? In the previous week, Avacta Group had 1 more articles in the media than Silence Therapeutics. MarketBeat recorded 2 mentions for Avacta Group and 1 mentions for Silence Therapeutics. Silence Therapeutics' average media sentiment score of 1.14 beat Avacta Group's score of 0.90 indicating that Silence Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Silence Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Avacta Group 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is SLN or AVCT more profitable? Silence Therapeutics has a net margin of 0.00% compared to Avacta Group's net margin of -114.45%. Silence Therapeutics' return on equity of 0.00% beat Avacta Group's return on equity.Company Net Margins Return on Equity Return on Assets Silence TherapeuticsN/A N/A N/A Avacta Group -114.45%-74.00%-21.80% SummaryAvacta Group beats Silence Therapeutics on 6 of the 10 factors compared between the two stocks. Get Avacta Group News Delivered to You Automatically Sign up to receive the latest news and ratings for AVCT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AVCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVCT vs. The Competition Export to ExcelMetricAvacta GroupBiotechnology IndustryMedical SectorLON ExchangeMarket Cap£181.22M£137.96M£5.70B£3.06BDividend Yield3.97%3.74%4.70%5.02%P/E Ratio-6.143.8028.27172.16Price / Sales6.894,698.95470.93272,145.30Price / Cash15.0013.1925.1827.97Price / Book3.2440.298.464.60Net Income-£30.08M-£90.99M£3.25B£5.90B7 Day Performance41.33%2.67%2.99%6.82%1 Month Performance49.34%8.65%11.05%13.91%1 Year Performance-33.75%188.93%34.28%68.86% Avacta Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVCTAvacta GroupN/AGBX 47.70+0.6%N/A-34.2%£181.22M£26.29M-6.14120Gap UpHigh Trading VolumeSLNSilence TherapeuticsN/AN/AN/AN/A£480.35M£11.35M-11.01100High Trading VolumePRTCPureTech Health1.9164 of 5 starsGBX 139+2.2%GBX 455+227.3%-19.9%£417.53M£521.32K-5.70300News CoverageOXBOxford Biomedica0.6456 of 5 starsGBX 383+2.4%GBX 390+1.8%+4.1%£407.13M£98.31M-2.85891News CoverageHZDHorizon Discovery Group plc (HZD.L)N/AN/AN/AN/A£302.98M£54.63M-33.55416FARNFaron Pharmaceuticals OyN/AGBX 197.50-0.3%N/A+35.7%£265.15MN/A-5.2834Gap DownVRPVerona Pharma plc (VRP.L)N/AN/AN/AN/A£228MN/A-1.6822Gap UpARIXArix BioscienceN/AN/AN/AN/A£183.73M£14.16M1,290.919BVXPBioventixN/AGBX 2,750+0.9%N/A-36.7%£144.00M£13.65M17.7912CIRCircassia GroupN/AN/AN/AN/A£142.66M£27.90M3,400.00111Gap Down4BB4basebioN/AGBX 979+1.5%GBX 1,600+63.4%-34.7%£125.41M£311K-1,255.13101 Related Companies and Tools Related Companies Silence Therapeutics Alternatives PureTech Health Alternatives Oxford Biomedica Alternatives Horizon Discovery Group plc (HZD.L) Alternatives Faron Pharmaceuticals Oy Alternatives Verona Pharma plc (VRP.L) Alternatives Arix Bioscience Alternatives Bioventix Alternatives Circassia Group Alternatives 4basebio Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:AVCT) was last updated on 7/28/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s $100 Trillion Land Rush Is OnWhat Is "The US: IPO"? You won't hear this on CNBC... but the government may soon open up hundreds of trill...Stansberry Research | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTop 10 Green Zone Stocks to Buy NowOthers have paid $2,000 for access to stock picks like these—this weekend, you can get them free. Using a p...TradeSmith | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avacta Group Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Avacta Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
